Patient-Based Therapeutics

AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

get to know us

Patient Focused

rp3.jpgrp1.jpgrp2.jpg

rp4.jpgThe main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes. 


learn about our work

Neurodegenerative Disease Areas

Latest News

July 25, 2025

AcuraStem Presents Advances in Patient-Derived Neurological Models and RNA Therapies at "Frontiers in Neuroscience"

At the symposium Frontiers in Neuroscience: Emerging Biology and Therapeutics, AcuraStem CEO Sam Alworth delivered a presentation titled “Using the iNeuroRx® Technology Platform to Develop Disease‑Modifying Treatments for ALS and FTD: Spotlight on UNC13A Candidate AS‑241.”

» Read more
February 7, 2025

AcuraStem Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan Chang, Presents at the 15th Annual ALS Network Research Summit

At the 15th annual ALS Network Research Summit, held on January 16, AcuraStem's Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan Chang delivered a key presentation titled 'Development of an UNC13A ASO for ALS.'

» Read more
December 20, 2024

AcuraStem CSO Marcel van der Brug Presents at the 35th International Symposium on ALS/MND

At the 35th International Symposium on ALS/MND, held from December 6-8, 2024, at the Montreal Convention Center, AcuraStem Chief Scientific Officer Marcel van der Brug delivered a key presentation titled 'Development of an UNC13A Cryptic Exon Skipping Antisense Oligonucleotide as a Treatment for ALS.

» Read more

Keep Up to Date with AcuraStem